...
首页> 外文期刊>Journal of obstetrics and gynaecology: the journal of the Institute of Obstetrics and Gynaecology >Therapy side-effects and predictive factors for preterm delivery in patients undergoing tocolysis with atosiban or ritodrine for threatened preterm labour
【24h】

Therapy side-effects and predictive factors for preterm delivery in patients undergoing tocolysis with atosiban or ritodrine for threatened preterm labour

机译:接受阿托西班或利多君溶栓治疗有威胁早产的患者早产的治疗副作用和预测因素

获取原文
获取原文并翻译 | 示例
           

摘要

The objective of this study was to compare the safety and efficacy of atosiban and ritodrine in the treatment of threatened preterm labour (TPL) and to analyse the predictive factors of preterm delivery. We retrospectively sampled data on 380 women hospitalised for TPL (24-35 weeks' gestation), in our clinic between 2004 and 2007. All were subjected to tocolysis with ritodrine and/or atosiban. Data were analysed using R (version 2.12.1), considering p < 0.05 as significant. We had 69 women treated with atosiban, 242 treated with ritodrine and 69 treated with ritodrine changed for atosiban, if adverse effects occurred. In the multivariate logistic regression, the use of atosiban vs ritodrine does not play any role in delaying delivery after 48 h or 7 days, whereas the cervical change at the digital examination, high contractions pre/post-therapy ratio, pPROM, cervical length and fibronectin result as predictive factors for both delivery before 48 h or 7 days. Maternal adverse drug effects were significantly more frequent in patients treated with ritodrine, and one single case of pulmonary oedema was observed. We found fewer side-effects in the atosiban than in the ritodrine group and no difference in efficacy. Moreover, the most predictive factors for preterm delivery were fibronectin test, pPROM, digital vaginal examination and uterine contraction persistence. We believe that predictive capacity of these tests could give the opportunity for targeting therapy and limiting drug side-effects and cost.
机译:这项研究的目的是比较阿托西班和利多君在先兆早产(TPL)治疗中的安全性和有效性,并分析早产的预测因素。我们回顾性抽取2004年至2007年间在我们诊所接受TPL住院治疗(妊娠24-35周)的380名妇女的数据。所有妇女均接受了利多君和/或阿托西班的安胎。考虑p <0.05为显着性,使用R(2.12.1版)分析数据。如果发生不良反应,我们有69名接受阿托西班治疗的妇女,242名接受了利多君治疗的妇女和69名接受了利多君治疗的妇女改用阿托西班治疗。在多因素logistic回归分析中,使用阿托西班vs利多君对延迟48 h或7天分娩没有任何作用,而数字检查时宫颈的改变,治疗前后的高收缩率,pPROM,宫颈长度和纤连蛋白可作为48 h或7天之前分娩的预测因素。接受利多君治疗的患者中,孕妇的不良药物作用更为频繁,并且观察到一例肺水肿。我们发现阿托西班的副作用比利多君组少,且疗效无差异。此外,早产的最预测因素是纤连蛋白测试,pPROM,数字阴道检查和子宫收缩持续性。我们相信这些测试的预测能力可以为靶向治疗和限制药物副作用和成本提供机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号